These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 7715293)

  • 21. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
    Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
    Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
    McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
    Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
    Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
    Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
    Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a live, oral, attenuated vaccine against El Tor cholera.
    Taylor DN; Killeen KP; Hack DC; Kenner JR; Coster TS; Beattie DT; Ezzell J; Hyman T; Trofa A; Sjogren MH
    J Infect Dis; 1994 Dec; 170(6):1518-23. PubMed ID: 7995992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.
    Chan M; Cheong TG; Kurunathan S; Chandrika M; Ledon T; Fando R; Lalitha P; Zainuddin ZF; Ravichandran M
    Microb Pathog; 2010 Nov; 49(5):211-6. PubMed ID: 20558271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.
    Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
    J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholera vaccines.
    Ryan ET; Calderwood SB
    Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.
    Migasena S; Pitisuttitham P; Prayurahong B; Suntharasamai P; Supanaranond W; Desakorn V; Vongsthongsri U; Tall B; Ketley J; Losonsky G
    Infect Immun; 1989 Nov; 57(11):3261-4. PubMed ID: 2807523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
    Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
    Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139.
    Waldor MK; Tschäpe H; Mekalanos JJ
    J Bacteriol; 1996 Jul; 178(14):4157-65. PubMed ID: 8763944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.